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Many cell surface glycoproteins are anchored to the membrane via a hydro-
phobic transmembrane polypeptide segment and a hydrophilic cytoplasmic tail .
In contrast, recent studies (1, 2) have shown that some cell surface proteins lack
a transmembrane polypeptide domain and are anchored to the cell surface via
an unusual glycolipid moiety containing phosphatidylinositol . These proteins can
be removed from the cell surface by phosphatidylinositol-specific phospholipase
C (PIPLC)' (3-8) . The significance of this unusual anchorage to the membrane
is not yet clear. However, some of these proteins, like Thy-1 and Ly-6/T cell
activation protein (TAP) in the mouse, were shown to be involved in T cell
activation and signal transduction (9-12) . We have examined immunologically
important cell surface glycoproteins found on human cells for attachment to the
membrane by the phosphatidylinositol glycolipid moiety . For this purpose we
have analyzed cells from paroxysmal nocturnal hemoglobinuria (PNH) patients
for expression of surface antigens, since recent studies have shown that the
molecules deficient in PNH, i.e ., acetylcholinesterase (13, 14), decay-accelerating
factor (DAF) (15-17), and alkaline phosphatase (18), are anchored to the mem-
brane via a phosphatidylinositol moiety (19-22) .
PNH is an acquired bone marrow clonal disorder (23, 24) . Patients with PNH
have abnormal erythrocytes (E) that are more sensitive to complement-mediated
lysis than normal erythrocytes . Three different categories ofE have been defined
inPNH based on their sensitivity to complement-dependent lysis (25-27) . Type
I E show normal sensitivity, whereas type II and type III E are 3-5 and 15-25
times more sensitive to complement-mediated lysis, respectively, than type I E.
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Type II E have been shown to be deficient in the complement regulatory protein
called DAF (15-17). Cell surface DAF inhibits the assembly of C3 convertases
and thereby regulates the complement cascade (28, 29). In type III E, in addition
to DAF, another factor that regulates the assembly of terminal complement
components known as homologous restriction factor (HRF) is deficient (30, 31).
In PNH patients, neutrophils, monocytes, lymphocytes, and platelets, as well as
E, may be deficient in DAF (32, 33), suggesting the defect can arise in a
pluripotent stem cell .
Here we show that lymphocyte function-associated antigen 3 (LFA-3) is
deficient in PNH cells and can be released from normal cells by PIPLC treatment.
LFA-3 is a cell surface glycoprotein of 45-70 kD widely distributed both on
hematopoietic and nonhematopoietic cells (34-36). Recent studies have shown
that LFA-3 is a ligand for the T cell glycoprotein CD2 (also known as T11, LFA-
2, and the E-rosette receptor). Interaction between CD2 and LFA-3 mediates
CTL adhesion to target cells (37, 38), thymocyte adhesion to thymic epithelial
cells (39), and rosetting of activated T lymphocytes with autologous E (40, 41) .
We find that LFA-3-deficient PNH E are deficient in adhesion to T cells in the
rosetting assay and in binding of "'I-CD2. These defects are corrected by
incorporating purified LFA-3 molecules into PNH E.
Materials and Methods
Reagents.
￿
FCS, RPMI 1640, HBSS, and gentamycin were from Gibco Laboratories,
Grand Island, NY. FCS was heat inactivated at 56°C for 30 min before use. FITC-
conjugatedgoat anti-mouse IgG was purchased from Zymed Laboratories, San Francisco,
CA. OVA (grade V) and aprotinin were purchased from Sigma Chemical Co., St. Louis,
MO. Anticoagulant citrate dextrose (ACD) was from Fenwal Laboratories, Deerfield, IL.
mAbs used were: TS2/9 specific for LFA-3 (34), 1A10 specific for DAF (33), L180/1
specific for sheep T1 ITS (42), W6/32 (HLA-AB) (43), TSI/22 (LFA-1) (34), TS2/18
(CD2) (34), OKMI (Mac-1) (Ortho Pharmaceutical, Raritan, NJ), Leu-2a (CD8), and Leu-
3a (CD4) (Becton Dickinson & Co., Mountain View, CA). P3 X63, a myeloma IgG, was
used as a nonbinding control. All washings, incubations, and dilutions were done with
10% FCS/RPMI. PIPLC was purified from Staphylococcus aureus bacterial culture super-
natant as described (44).
Patients and Controls. Blood samples were collected from PNH patients and from
normal individuals either in ACD or in Heparin (10 U/ml) as anticoagulants. PNH patients
DE and PK had type III E. Patients SB, MW, and CP had type II E. PatientJB had both
type II and type III E. As a control, blood was drawn from healthy donors at the same
time and processed similarly.
Cells.
￿
Leukocyte-rich plasma was separated from E by 6% dextran (Pharmacia Fine
Chemicals, Piscataway, NJ) sedimentation. The separated E were stored as such at 4°C
upto I mo ifthe blood wascollected in ACD or washed fivetimes with 10% FCS/RPMI/gen-
tamycin and resuspended in the same medium before storage if the blood was collected
in heparin. E were washed three to five times with 10% FCS/RPMI/gentamy-
cin before use. Jurkat cells, a human T lymphoma cell line, were grown in 10%
FCS/RPMI/gentamycin and washed thrice with 10% FCS/RPMI/gentamycin before use
in the rosetting assay.
Immunofluorescence Flow Cytometry.
￿
E were washed three to five times and resuspended
at a concentration of 5 X 10' cells/ml. An aliquot of 50 ul of cells (5 X 106 cells) were
incubated with an equalvolume of specific antibody for 30 min at 4°C. Specific antibodies
in hybridoma culture supernatants or in diluted ascites were used at saturating concentra-
tions. The cells were washed thrice and further incubated with FITC-conjugated goat
anti-mouse IgG for 30 min at 4 °C. Then the cells were washed thrice, resuspended, andSELVARAJ ET AL.
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analyzed in an Epics V flow cytometer (Coulter Electronics Inc., Hialeah, FL). A minimum
of 10,000 cellswere analyzed per experiment. As a nonspecific control, X63, a nonbinding
myeloma IgG, was used.
1251-CD2BindingAssays.
￿
12'I-labeled purified CD2 antigen was prepared as previously
described (38). The '21I-CD2 binding assays were carried out as follows: washed E (5 x
106 cells) were incubated with either 50 ,l of antibody or 50 ,l of 10% FCS/RPMI for 45
min at 4°C in a microtiter plate pretreated with 10% FCS/RPMI. Then 50,,1 of varying
concentrations of '25I-CD2 diluted in 3% BSA/10% FCS/RPMI was added and the
incubation was continued for another 2 h at 4°C with continuous shaking. The cells were
washed thrice with 10% FCS/RPMI, resuspended, and counted in a gamma counter.
Under the experimental conditions used no lysis of E was observed during the binding
studies.
Rosetting Assay.
￿
Rosetting ofJurkat cells with human E was carried out as described
(41). Briefly, 100 IAl of 106 Jurkat cells/ml were mixed with 100 11 of 10' E/ml at 37°C
for 5 min and incubated for 2 h at 4 ° C. The cells were gently resuspended and Jurkat
cells rosetting with a minimum of three E were scored as rosettes. Because of the day-to-
day variations in the percent ofJurkat cells rosetting with control human E, rosetting of
PNH E was always compared with the rosetting of normal control E counted in parallel.
Incorporation ofPurified LFA-3 into E.
￿
LFA-3 was purified from human E to homoge-
neity using TS2/9-Sepharose affinity chromatography as described (40). The LFA-3
eluate (50 ug/ml in nine parts 50 mM glycine/HCI buffer, pH 2.5, 0.1% Triton X-100,
and one part of 1 M Tris/HCI, pH 8.6) was diluted 100 times with HBSS, added to
packed E to give a final concentration of 10' cells/ml, and incubated for 4 h at 37°C
during gentle end-over-end rotation. The tube was filled except for a small air bubble.
As a control, an aliquot of PNH or normal E was incubated in parallel with an identical
buffer lacking LFA-3. After incubation the E were washed thrice with 10% FCS/RPMI.
Under these conditions no cell lysis was observed.
PIPLC Treatment of Cells.
￿
Washed E or JY cells, a B lymphoblastoid cell line, were
incubated with HBSS/2 mM Hepes, pH 7.4, or PBS, pH 7.4, containing 1 mg/ml OVA
and 10 kg/ml of PIPLC at 37°C for 1 h. Then the cells were washed and analyzed for
surface antigens by immunofluorescence flow cytometry or immunoprecipitation. As a
control, the cells were incubated under identical conditions but without PIPLC.
Immunoprecipitation and SDS-PAGE. JY cells were surface iodinated with '25I using
1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril as described (45). Aliquots of the labeled
cells were incubated with or without PIPLC as described above for 1 h at 37°C and
centrifuged at 1,000 g for 7 min. The supernatant was further centrifuged at 100,000g
for 1 h and saved for immunoprecipitation. The 1,000 gcell pellet was washed with HBSS
and lysed in 1% Triton X-100 in 10 mM Tris/HCI/145 mM NaCl/0.02% NaN3, pH 8.0,
containing 1 % bovine hemoglobin, 1 mM iodoacetamide, 1 mM PMSF, and 1 % aprotinin.
The LFA-3 in the supernatants and the lysates was immunoprecipitated with TS2/9-
Sepharose and subjected to SDS-PAGE (46) under reducing conditions. The gel was dried
and autoradiographed.
Results
Deficient LFA-3 Expression on PNH E.
￿
Patient DE was deficient in DAY in E,
lymphocytes, granulocytes, and monocytes as previously described (33). mAb
staining of these cells in patient DE showed normal expression of LFA-1, CD2,
CD4, CD8, and HLA-A, B. However, DE E were almost completely deficient in
LFA-3 (Fig. 1 A). Deficiency of LFA-3 on E was verified in further PNH patients
(Fig. 1 B-E). The severity of LFA-3 deficiency varied. For patient DE, nearly
90% of E had little or no LFA-3 and 10% had subnormal levels of LFA-3 (Fig.
1 A). Patient SB showed three different populations. -10% of the E expressed a
normal level of LFA-3, 70% of the E expressed a subnormal amount of LFA-3
and 20% showed no LFA-3 expression (Fig. 1 B). Patients JB, MW, and CP had1014 LFA-3 DEFICIENCY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
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FIGURE 1 .
￿
Fluorescent staining of LFA-3 and DAF on PNH and healthy control E. E were
incubated with LFA-3 mAb (solid lines), anti-DAF mAb (dashed lines), or X63, control IgG
(dotted lines), stained with fluorescein-labeled goat anti-mouse IgG, and subjected to immu-
nofluorescent flow cytometry . Matched controls areshown for each patient since fluorescence
amplification settings varied forsome of the patients .
two distinct populations ; one totally deficient in LFA-3, and a second population
with subnormal or normal amounts ofLFA-3 . DAF deficiency paralleled LFA-3
deficiency, but was not always identical to that of LFA-3 . LFA-3 deficiency was
not as marked as DAF deficiency in patients JB, SB, and CP .
' 257-CD2 Binding to PNH Erythrocytes .
￿
Previous studies (37-41) have shown
that the T lymphocyte surface glycoprotein CD2 is a receptor for LFA-3.
Detergent-solubilized, purified CD2 binds to cell surface LFA-3 (38, 41). PNH
erythrocytes showed reduced binding of 1251-CD2 (Fig . 2) . Compared with
controls, E from patient DE showed 13% 1251-CD2 binding, whereas E from
patients PK, JB, and SB showed 48, 44, and 33% 1251-CD2 binding . Binding of
CD2 by PNH E correlated with LFA-3 expression (compare Fig. 1 and Fig . 2) .
Rosetting ofPNH E with furkat Cells.
￿
Previously we have shown (40, 41) that
the autologous rosetting of human T lymphocytes with E is mediated by the
CD2 and LFA-3 receptor-ligand interaction. We examined whether the de-
creased LFA-3 expression on PNH E correlated with a defect in adherence
(rosetting) to T cells (Table I) . The T lymphoma cell line Jurkat was used ina z
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TABLE I
PNH E are Deficient in T Lymphocyte Rosetting
FIGURE 2.
￿
1251-CD2 binding to PNH E
andcontrol E. PNH and control E (5 X
106) were incubated with subsaturating
concentrations of 1251-CD2 (input of
100,000 cpm) andthe bindingassaywas
carried outas describedin Materials and
Methods. The amount of CD2bound to
normal control E at the highest concen-
tration of added 1251-CD2 was taken as
100%. The s~ecific activity of '251-CD2
was 3.8 X l0 cpm/nmol.
* DE (1) and DE (2)areEobtained from thesame patient at twodifferent
blooddonationswith 7-wk intervals.
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rosetting assays because it is a higher expressor of CD2 (47), and rosettes well
with human E (41). PNH E were deficient in the rosette assay, and the degree
ofdeficiency in rosetting correlated with the extent ofLFA-3 deficiency. Rosettes
with PNH E also contained fewer E, ranging from 3-5 for DEand SB, compared
with 5-20 for control E.
Correction of Functional Defects by Incorporation of Purled LFA-3 into PNH
E. When exogenous, purified LFA-3 (0.5 ug/ml) was incubated with PNH or
control E at 37°C it was readily incorporated into the E membrane (Fig. 3). The
incorporated LFA-3 was stable on the cell surface and was not removable by
repeated washing with PBS, HBSS, or 10% FCS/RPMI. Storage of washed E at
4°C for up to I wk did not result in lossofincorporated LFA-3 (data not shown).
LFA-3 could be incorporated into PNH E (Fig. 3, A-C, bottom panels) in higher
amounts than found on untreated control E (Fig. 3D, top panel). Incorporation
of exogenous LFA-3 did not alter staining with DAF mAb (Fig. 3). This
demonstrates that LFA-3 and DAF are different molecules. These molecules
also differed in side-by-side SDS-PAGE ; LFA-3 is a diffuse band of 43-68 kD,
whereas DAF is a sharp band of70 kD (data not shown).
Exp. Patient
Rosetting
lymphoma
Control E
Jurkat T
cells
Patient E
Patient E (per-
cent of control)
1 DE (1)* 52 3 6
2 DE (2)* 42 4 11
3 SB 71 11 20
4 PK 69 28 38
5 JB 51 22 43
6 MW 66 44 67
7 CP 61 31 511016 LFA-3 DEFICIENCY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
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FIGURE 3 . Incorporation of
exogenous LFA-3 into PNH
and control E. E were incu-
bated with purified LFA-3 or
with control buffer as de-
scribed under Materials and
Methods . Washed cells were
stained with LFA-3mAb (solid
lines), or anti-DAF mAb
(dashed lines) or control IgG
(dotted lines), and fluorescein
goat anti-mouse IgG .
FIGURE 4 . Incorporation of LFA-3 into
PNH Eandhealthy controlEaugments 1211-
CD2 binding, LFA-3 wasincorporated into
E and 1x51-CD2 binding was carried out as
described under Materials and Methods . 5
x 106 cells and 100,000 cpm of 's5I-CD2
were used per assay point . Each point rep-
resents the average of duplicates . Binding
of ßs51-CD2 after pretreatment ofcells with
LFA-3 mAb was tested in all experimental
groups and was x = 6%, range = 0-14% of
binding in the absence of pretreatment.
We determined whether functional defects in ability to bind purified CD2 and
rosette withT lymphocytes were due to deficiency ofLFA-3 or to the deficiency
ofother affected phosphatidylinositol-linked surface proteins . The reconstituted
cell preparations analyzed for LFA-3 incorporation in Fig . 3 were tested forCD2
binding (Fig . 4) . Reconstitution of DE, JB, and PK E with exogenous LFA-3
reconstituted '251-CD2 binding . Addition of exogenous LFA-3 to normal E also
resulted in increased "5I-CD2 binding . The amount of 125I-CD2 binding corre-TABLE II
Incorporation ofExogenous LFA-3 Reconstitutes Rosetting
SELVARAJ ET AL.
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Patient or control E were incubated with purified LFA-3 and rosetted
with Jurkat T lymphoma cells as described under Materialsand Methods.
lated with the amount of cell surface LFA-3 (compare Fig. 3 and Fig. 4). The
binding of '251-CD2 was completely inhibited by pretreating the E with anti-
LFA-3 antibody, indicating that it was due to specific binding of 1251-CD2 to cell
surface LFA-3.
Incorporation of LFA-3 into PNH E reconstituted E rosetting toJurkat cells
(Table II). The percentage ofJurkat cells rosetting with E correlated with the
amount of LFA-3/E, and LFA-3 reconstituted in PNH E to higher levels than
present on untreated controls resulted in a higher percentage of rosetting than
with untreated control E. Incorporation ofexogenous LFA-3 into control E also
augmented rosetting.
PIPLC Treatment of Cells.
￿
LFA-3 deficiency in PNH suggested that this
antigen is attached to cell membranes via a glycolipid tail containing phosphati-
dylinositol. Nearly 35% of LFA-3 was removed from the surface of JY (a B
lymphoblastoid cell line) cells by PIPLC treatment (Fig. 5A). The decrease in
cell surface LFA-3 after PIPLC treatment was specific because other membrane
proteins like HLA-A, B and LFA-1 were not affected, whereas, under the same
conditions nearly 62% of the DAF was released from the membrane. PIPLC
treatment of 1251-labeled cells confirmed that the released LFA-3 could be
recovered from the supernatant by immunoprecipitation (Fig. 6).
PIPLC treatment did not release a significant amount ofendogenous LFA-3
from E (Fig. 5B); however, E DAF and acetylcholinesterase, which have been
shown to be linked via phosphatidylinositol to the E cell membrane, are also
resistant to PIPLC treatment on E (Fig. 5B, references 5, 20, 21, 48). DAF is
released from other cell types as reported previously (5) and confirmed in Fig.
5A. Some feature, either of the E surface or a specific modification of the
glycolipid moiety in E may render them resistant to PIPLC. However, when
purified erythrocyte DAF is incorporated into sheep E it becomes susceptible to
PIPLC treatment (21). We tested whether purified erythrocyte LFA-3 incorpo-
rated into sheep or human E was sensitive to PIPLC. Nearly 50% of LFA-3
incorporated into sheep E was released by PIPLC, whereas under the same
conditions sheep T11 ITS, the sheep homologue of LFA-3, was unaffected (Fig.
5C). Purified LFA-3 incorporated into human healthy control or PNH E was
similarly susceptible to PIPLC treatment (Fig. 5D).
Exp. Patient
Percentrosettingafter
treatment
None +LFA-3
1 Control 32 68
Patient PK 12 53
2 Control 56 ND
PatientJB 26 68
3 Control 74 81
Patient MW 45 85
Patient CP 28 811018 LFA-3 DEFICIENCY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
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FIGURE 5.
￿
PIPLC treatment ofJY cells and E. Cells were treated with 10 ug/ml of PIPLC
as described in Materials and Methods at 37°C. The cells were washed and incubated with
specific or control mAb, then stained with fluorescein-labeled goat anti-mouse IgG. Labeled
cells were analyzed by immunofluorescence flow cytometry. The specific linear fluorescence
(SLFI) of cells treated under the same conditions but without PIPLC was taken as 100%. (A)
JY cells. (B) Healthy control human E. (C) Sheep E with incorporated, purified LFA-3. (D)
Human Ewith incorporated, purified LFA-3 (open squares, PNH Etreated with LFA-3; closed
squares, control E treated with LFA-3).
Discussion
We have found that LFA-3 is deficient on E from patients with PNH, an
acquired hematopoietic clonal defect that affects the cell surface expression of
phosphatidylinositol-anchored membrane proteins . Previous studies (37-41)
have shown that LFA-3, a widely distributed cell surface glycoprotein, is a ligand
of the T lymphocyte surface glycoprotein CD2. Binding of CD2 to LFA-3
mediates antigen-independent adhesion of T lymphocytes to many types of cells
including target cells, thymic epithelial cells, and E. Adhesion via CD2/LFA-3 is
regulated by a number offactors including cell surface density of CD2 and LFA-
3, and by the cell surface charge (49). CD2' resting T lymphocytes do not rosette
with autologus LFA-3+ E, but do form rosettes if sialic acid is removed from
either cell. Furthermore, activated T lymphocytes and thymocytes, which have
more CD2 (50, 51) and two- and fivefold less sialic acid (52) than resting T
lymphocytes, respectively, readily rosette with human E. The previous conclusion
that CD2 binds to LFA-3 was based on competition between purified CD2 and
LFA-3 mAb for binding to cell surface LFA-3, and reciprocally, competition
between purified LFA-3 and CD2 mAb for binding to cell surface CD2 (38, 40,
41). Deficiency of LFA-3 on PNH E provided an independent means of testing
the interaction of CD2 with LFA-3, which to our knowledge is the first demon-SELVARAJ ET AL .
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FIGURE 6. SDS PAGE of LFA-3 released from cells by
PIPLC. Surface-iodinated JY cells (106 cells) were treated
with 0.28 M sucrose/25 mM Hepes buffer, pH 7.4, with or
without PIPLC (10 kg/ml) for 1 h at 37°C . LFA-3 was
immunoprecipitated from the supernatants and cell lysates
and subjected to SDS-12% PAGE under nonreducing con-
ditions . The gel wasdried andautoradiographed .
stration of an integral membrane adhesion receptor which binds a distinct
integral membrane ligand . E from our most severely affected PNH patient,
which were 91 %LFA-3 deficient, showed quantitatively similar defects in binding
of I25I-CD2 and rosetting with T lymphoma cells . Overall in six different PNH
patients that had varying proportions of affected E populations, there was an
excellent correlation between amount of cell surface LFA-3, 125I-CD2 binding,
and rosetting .
Similarly to DAF, which has a phosphatidylinositol membrane anchor (5, 21,
29), we found that purified LFA-3 could be readily incorporated into the
membrane bilayers of both PNH and control E. Incorporation of purified LFA-
3 into PNH E corrected the defects in 1251-CD2 binding and rosetting . Incorpo-
ration into normal E, resulting in increased cell surface LFA-3, augmented 1251-
CD2 binding and rosetting . The findings that LFA-3-deficient PNH E are
correspondingly deficient in binding purified CD2 and in rosetting with T
lymphocytes, and that reconstitution with LFA-3 corrects these defects, strongly
supports previous conclusions that CD2 binds LFA-3 (37-41) and that this
interaction mediates rosetting of T lymphocytes with autologous E (41) .
PIPLC specifically released LFA-3 from B lymphoblastoid cells, as determined
both by immunofluorescence and by immunoprecipitation . These results con-1020 LFA-3 DEFICIENCY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
firmed that LFA-3 is anchored to the membrane via phosphatidylinositol. PIPLC
did not release endogenous LFA-3 from E, but purified E LFA-3 that was
incorporated into sheep or human E was released by PIPLC. Whether this is due
to removal of an associated molecule or to cleavage of some portion of the
glycolipid moiety during purification, or reflects a difference between endoge-
nous and exogenous LFA-3 in the way they are incorporated in the membrane,
is not known . Endogenous E DAF, which has been shown chemically to be linked
to phosphatidylinositol,. is also largely PIPLC resistant (5, 21). Reports conflict
on whether exogenous DAF incorporated into E is sensitive to PIPLC (5, 21).
Using an excess of PIPLC, we consistently found a higher proportion of DAF
than LFA-3 was released from lymphoblastoid cells (62 vs. 35%). Since the work
reported here was completed, two lines of investigation have suggested that on
white blood cells LFA-3 is present in two forms, a phosphatidylinositol-linked
form and a distinct, putative hydrophobic polypeptide chain-linked form,
whereas on E predominantly the phosphatidylinositol-linked form is present.
First, on PNH monocytes and granulocytes that appear to be clonally affected as
shown by complete absence of DAF, LFA-3 is expressed but at slightly reduced
levels (Medof, M. E., P. Selvaraj, M. L. Dustin, D. G. Ayers, E. 1. Walter, H. A .
Stafford, R . Green, M. L. Tykocinski, and T. A. Springer, manuscript in
preparation). Secondly, biosynthesis experiments have demonstrated two forms
of LFA-3 that differ in size by 3 kD on many different types of nucleated cells.
The lower but not the higher molecular mass form is released from the cell
surface by PIPLC (Dustin, M. L ., P. Selvaraj, R. J. Mattaliano, and T . A .
Springer, submitted for publication).
Molecules deficient in PNH erythrocytes or leukocytes include DAF (15-17),
a protein important in assembly of the C8, C9 complex called HRF (30, 31),
acetylcholinesterase(13, 14), alkaline phosphatase (18), and now LFA-3. Linkage
of four of these proteins to phosphatidylinositol (linkage of HRF has not yet
been tested) suggests that the primary defect in PNH is related to the assembly
or the linkage of the phosphatidylinositol glycolipid moiety. The clinical symp-
toms in PNH appear due to absence of complement regulatory proteins DAF
(15-17) and HRF (30, 31), resulting in complement-mediated lysis of red blood
cells, and increased hematopoiesis. Although some impairment of immune func-
tion has been reported (53, 54), it is unclear whether this is related to deficiency
of LFA-3. Only one form of LFA-3 is deficient on white blood cells in PNH, as
mentioned above, and LFA-3 is expressed on some nonhematopoietic cell types
including endothelial and epithelial cells, which are unaffected in PNH.
The phosphatidylinositol glycolipid anchor of LFA-3 may be of physiologic
importance. The lateral mobility of two studied phosphatidylinositol-linked pro-
teins, DAF and Thy-1, is higher than for surface proteins with transmembrane
polypeptide chains (55, 56). Mutual redistribution of CD2 and LFA-3 to a site
of adhesion would be dependent on the ability of the receptor and ligand to
diffuse into the site ofcell-cell contact. Thus, the predicted high rate ofdiffusion
of LFA-3 may make it more effective in mediating cell adhesion. The phosphati-
dylinositol anchor may also be important in signaling. Recent studies (57) have
shown that the CD2- and LFA-3-dependent interaction of thymocytes with
thymic epithelial cells stimulates the latter cell type to secrete IL-1 . Furthermore,LFA-3 mAb mimics this by inducing IL-1 secretion by thymic epithelial cells and
monocytes (57). Whether signal transduction by LFA-3 or by other glycolipid-
anchored surface proteins (6, 10-12) is mediated by the phosphatidylinositol
moiety remains to be determined.
Summary
Lymphocyte function-associated antigen 3 (LFA-3) is a widely distributed cell
surface glycoprotein that binds to the T lymphocyte CD2 surface glycoprotein.
This interaction mediates CTL-target cell conjugate formation andadhesion of
thymocytes to thymic epithelial cells. CD2 is also the E rosette receptor of T
lymphocytes and mediates rosetting with autologous E by binding to LFA-3. We
describe deficient expression of LFA-3 on E from paroxysmal nocturnal hemo-
globinuria (PNH) patients. PNH is an acquired defect affecting phosphatidyli-
nositol-anchored membrane proteins, of which decay-accelerating factor (DAF)
is most important in the clinical symptoms of PNH. LFA-3-negative, weakly
positive, and positive populations were found among PNH E. There was a good
correlation with DAF deficiency. PNH E exhibited decreased binding of '25I-
CD2 and rosetting with a human T lymphoma cell line. PNH E readily incor-
porated purified LFA-3, restoring LFA-3 expression and the CD2 binding and
rosetting activity to normal levels. The expression of DAF was not restored after
the incorporation of purified LFA-3 into PNH E, showing that LFA-3 and DAF
are different molecules. Phosphatidylinositol-specific phospholipase C (PIPLC)
treatment of a B lymphoma cell line released 35% of the cell surface LFA-3 and
62% of DAF. LFA-3 on E was resistant to PIPLC. However, when LFA-3
purified from human E was reconstituted in sheep E or human E and subjected
to PIPLC treatment, 40-50% of LFA-3 was released from the cell membrane.
The results show that LFA-3 is attached to the cell membrane by a phosphati-
dylinositol glycolipid moiety, and confirm previous findings (37-41) that LFA-3
is a cell adhesion molecule that mediates adhesion by interacting with CD2
antigen.
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